DIVINA 2MG + 2MG/10 MG TBL NOB 3X21

What is the maximum co-payment for DIVINA?

If the insurance company contributes, the maximum co-payment is 61,61 Kč. The maximum pharmacy price is 260,94 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but the reimbursement conditions (reporting limit) have not been set.

Does DIVINA have a counted co-payment set?

Yes, the medicine has a counted co-payment of 61,00 Kč. Learn more about the protective limit here.

How much does the insurance company pay for one dispensed reimbursed pack?

199,33 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

The medicine has no indication restriction. Its reimbursement is not conditional on a specific diagnosis or clinical condition.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe DIVINA?

Prescription is not conditional on a medical specialization.

What is the composition of DIVINA?

Estradiol-valerát (2 mg), monohydrát laktosy, kukuřičný škrob, želatina, ointmentek, magnesium-stearát, medroxyprogesteron-acetát (10 mg), indigokarmín, povidon k 25. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to DIVINA?

The medicine belongs to ATC group G03FB06 – MEDROXYPROGESTERON A ESTROGEN. Medicines with the same active substance can be found here.

Who manufactures DIVINA?

Orion Corporation, Espoo (SF)

Is the medicine in shortage?

The latest report from the manufacturer is from 10. 3. 2025. Production was terminated with effect from 10. 5. 2025. The manufacturer lists medicines with the following code as a potential substitute:
The product has no substitute listed.Note provided: V rámci dané ATC skupiny bez náhrady; náhrada jinými přípravky pro hormonální substituční terapii (HRT) dle rozhodnutí ošetřujícího lékaře.